Schedule

7.00-7.30 am: Registration

7.25-7.30 am: Opening remarks- Banke Agarwal, MD
7.30-9.15 Session I

Multidisciplinary management of tumors of the liver and bile ducts
Moderators: David Linehan and Betsy Tuttle-Newhall

7.30-7.45   Patient with obstructive jaundice and intra-hepatic biliary dilation with normal sized CBD - Martin FreemanDownload PDF
  • ERCP: is it really needed and if yes, when to perform, by whom, and where
  • Transaxial imaging : when should it be performed and what kind of imaging is appropriate
  • Multi-disciplinary evaluation and management
  • Tissue diagnosis of cholangiocarcinoma: how to obtain tissue, what are the acceptable gold standards
  • Patients with PSC: when to suspect cancer and how to diagnose it
7.45-8.00   Hepatocellular carcinoma: when to suspect and how to diagnose: Luis Balart Download PDF
  • Role of tissue diagnosis in patients with suspected HCC
    • potential benefits
    • whom
    • how
  • Screening and surveillance for HCC
    • tumor staging
    • co-morbidities
  • Treatment considerations in patients with suspected HCC
8.00-8.15  State-of-the-art imaging for hepatic malignancy: Elliot Fishman Download PDF
  • CT vs MRCP
    • which one to choose for HCC vs. cholangioCA
    • what special protocols to use for liver tumors
  • Role of PET and Duplex US in these patients
  • Evaluating resectablity in hilar cholangioCA
  • Diagnostic accuracy of radiologic imaging for cholangioCA and HCC
8.15-8.30   Management of hilar and intrahepatic cholangiocarcinoma : Charles B. Rosen Download PDF
  • Resection vs. transplantation
  • Which patients are eligible for transplantation
  • How to determine resectability for hilar and intrahepatic cholangioCA
  • What to do if tissue diagnosis of cholangioCA cannot be established
  • Outcomes of surgery for cholangioCA
  • Malignant masquerades:  how they are dealt with surgically and their outcomes
8.30-8.45   Management of hepatocellular carcinoma:  Pierre A. Clavien Download PDF
  • Patient selection: expanding Milan criteria
  • Patients with hepatitis B vs. hepatitis C
  • Bridging therapies
    • transarterial chemo-embolization
    • percutaneous ethanol injection
  •  Patient selection for definitive therapy
  • Role in down staging HCC
  • Combination therapy
    • RFA
    • radiation
    • systemic therapy

8.45-9.15Q&A and Case discussions

9.15 – 9.30Coffee Break

9.30 – 11.00Session II
Small bowel neoplasms 
Moderators:  Sreenivasa Jonnalagadda and Steven Fern
9.30-9.50   Gastroenterologist’s perspective – Lauren Gerson Download PDF
  • What clinical presentations should prompt small bowel imaging for tumors
  • How to choose between capsule endoscopy and DBE
  • Common tumors noted in small bowel by CE and DBE
  • What if both CE and DBE are negative?  Should CT or MR enterography be performed
  • Mass lesions seen on CE: how to further manage these patients?
9.50-10.10  Radiologic Imaging for small bowel tumors-Elliot Fishman    Download PDF
  • Available radiologic imaging tests for patients suspected small bowel tumors
  • Indications for using small bowel imaging
  • Radiologic findings for the different small bowel tumors
  • Radiation risk to patients undergoing these evaluations
10.10-10.30   Surgical perspective- Robert R. Cima Download PDF
  • Common clinical presentations of small bowel tumors presenting to a surgeon
  • Appropriate pre-operative work-up in a patient with small bowel tumor noted on imaging is a tissue diagnosis necessary
  • What are the different surgical procedures for the different small bowel tumors
  • Expected outcomes in patient s with small bowel tumors
  • How to follow up these patients after surgery

10.30-11.00Q&A  and case discussions

11.00 -12.00Dealing with conflicts in Healthcare setting

Panel:   Andrew Schlafly, Larry Huntoon , Shaun Falvey

12.00-1.00Lunch

1.00 – 2.30Session III
Diagnosis and management of pancreatic cancer:  common dilemmas
Moderators:  Banke Agarwal and Paul Buse
1.00-1.15   Evaluation of patients with obstructive jaundice and dilated CBD without stones in CBD or gallbladder - Robert Hawes Download PDF
  • What transaxial imaging to perform prior to ERCP
  • What to do if no mass is identifiable on CT/MRI
  • Role of EUS-FNA  in these patients
  • Staging of pancreatic cancers: role of EUS
  • ERCP for biliary drainage : how to decide who would benefit
1.15-1.30   What to do and not do before seeking surgical consultation for patient with suspected pancreatic cancer – Carlos Fernandez-del-castillo Download PDF
  • Common pitfalls in management prior to surgical consultation for pancreatic cancer
  • Value of EUS-FNA in patients with obstructive jaundice
    • and mass lesion on CT scan
    • no identifiable mass lesion on CT scan
  • Non-jaundiced patient with potentially resectable mass in body of pancreas
    • should tissue diagnosis be obtained prior to surgery
  • What is appropriate staging work-up for patient with pancreatic cancer
1.30-1.45  Is R1 or R2 resection of pancreatic adenocarcinoma of any benefit or does it just increase morbidity – Robert Wolff Download PDF
  • What is comparative survival in pancreatic cancer patients with R0, R1 and R2 resection and how does it compare with patients who elect not have surgery
  • How accurate is the radiologic imaging for staging pancreatic cancer
    • do R1 and R2 resections occur only in patients with borderline resectable tumor on CT/MRI
  • Borderline resectable tumors
    • how to define them
    • should they always receive pre-operative chemoradiation
  • Unresectable pancreatic tumors in younger individuals- Is aggressive therapy worth it for the patient

1.45-2.30Q&A and case discussions

2.30-3.30Session IV
Health Care reform and future of medicine
Moderators:  Keith Naunheim and Ira Kodner

Health care reforms:  Physician’s perspective – John Matthew Inadomi, M.D.
Health care reforms: Hospital’s perspective - David Applington
Health care reforms: How it is likely to affect private practice - John Allen

Session IV - Diagnosis and management of pancreatic cancer.pdf

3.30-3.45Coffee break

3.45-5.15 pmSession V
Information you should have to make the correct treatment choice in patients with Barrett’s  esophagus
Moderators: Michael Presti and Charlene Prather
3.45-4.00   Epidemiology of Barrett’s esophagus and cancer risk - Glenn EisenDownload PDF
  • Degree of dyplasia and risk of cancer
  • Are there molecular markers that are associated with increased risk of cancer
  • Does presence of severe GE reflux increase the risk of Barrett’s associated cancer
  • Barrett’s Surveillance: is it worth the cost
  • What are optimal intervals between endoscopy for Barrett’s surveillance
  • Barrett’s with dysplasia on biopsy
    • should be biopsies always be reviewed by a second pathologist
    • what if the pathologists differ in their interpretation of dysplasia
  • Barrett’s with high grade dysplasia in the background of inflammation
    • when should the biopsies be repeated
    • what if the inflammation does not resolve on repeat biopsies
4.00-4.15   Medical treatment of Barrett’s esophagus – Kenneth WangDownload PDF
  • Role of PPIs: what is the benefit, what is the supporting data
  • Role of ASA: what is the benefit, what is the supporting data
  • Do they reduce cancer risk and by how much
  • Who should be treated
4.15-4.30   Surgical treatment for Barrett’s esophagus - Jeffrey Peters Download PDF
  • What are the current indications for surgery in patients with Barrett’s esophagus
  • What are the various kinds of esophageal surgeries performed in these patients and what are their relative advantages and disadvantages
  • What is the risk of post-operative complications
  • What is the expected quality of life after esophagectomy
4.30-4.45   Endoscopic therapy of Barrett’s esophagus - Nicholas Shaheen Download PDF
  • Indications for Radiofrequency ablation for Barrett’s esophagus
  • What are the potential complications of RFA
  • What is achieved by ablation of Barrett’s by RFA
    • does the cancer risk decrease
    • do the patients still need to be on surveillance
  • Potential role of Cryoablation for Barrett’s treatment - how does it compare with RFA

4.45-5.15Q&A and case discussions

5.15 pmConference adjourned

 

NOTE: Any and/or all workshop syllabus materials on this site are for the exclusive use of the faculty and participants of the workshop. Any copying, duplicating or reproducing of any and/or all workshop syllabus materials by electronic, mechanical or other means for any purpose other than this workshop is strictly prohibited without prior written consent of the author of those workshop syllabus materials.

Co-Sponsors:

ASGE designates this activity for a maximum of 8.25 AMA PRA Category 1 Credits.
For additional information, call 314-977-7401.